心血管疾病的细胞衰老和衰老疗法。

Q1 Pharmacology, Toxicology and Pharmaceutics
Advances in pharmacology Pub Date : 2025-01-01 Epub Date: 2025-02-24 DOI:10.1016/bs.apha.2025.01.019
Arttatrana Pal
{"title":"心血管疾病的细胞衰老和衰老疗法。","authors":"Arttatrana Pal","doi":"10.1016/bs.apha.2025.01.019","DOIUrl":null,"url":null,"abstract":"<p><p>Cellular senescence (CS) is characterized by stable cell cycle arrest and is resistant to growth-promoting stimuli allied with aging. Cardiac senescent cells (SCs) are highly heterogeneous cells that can regulate the pathophysiology of cardiovascular diseases (CVDs). SCs accumulate in the cardiovascular system, leading to typical age-related cardiovascular conditions. Such conditions advance in cardiovascular pathologies, including heart failure, coronary artery disease, cardiac fibrosis, etc., by evocating the production of proinflammatory mediators and profibrotic senescence-associated secretory phenotype (SASP). SCs release different factors depending on the cell type that became senescent. Many factors are responsible for CS with the aging process. The primary senescence causes are oxidative stress, metabolic dysfunction, telomere shortening, and epigenetic deregulation. However, it isn't easy to understand the molecular mechanisms that lead to CS and the consequences of CS in developing new strategies and therapeutic approaches to treat CVDs. Among all, senotherapies are an emerging approach for intervening against CS mechanisms in CVDs to potentially prevent and treat CVDS. Senotherapies allow targeting the underlying causes of aging rather than treating disorders and could reduce polypharmacy. Essentially, senotherapeutics represent an emerging anti-SC treatment and comprise three therapeutic approaches such as molecules to selectively kill SCs that are defined senolytics, compounds able to reduce evocated SC SASP, acting hence as SASP suppressors, called senomorphics, and inhibition of increase of the number of SCs in the cardiovascular tissues. Senotherapies might delay or prevent the CVDs in the elderly. Therefore, senotherapeutics represent the potential clinical application in CVDs, stressing benefits and signifying potential solutions for applying them as soon as effective anti-CVD treatments.</p>","PeriodicalId":7366,"journal":{"name":"Advances in pharmacology","volume":"104 ","pages":"313-349"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Cellular senescence and senotherapeutics in cardiovascular diseases.\",\"authors\":\"Arttatrana Pal\",\"doi\":\"10.1016/bs.apha.2025.01.019\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Cellular senescence (CS) is characterized by stable cell cycle arrest and is resistant to growth-promoting stimuli allied with aging. Cardiac senescent cells (SCs) are highly heterogeneous cells that can regulate the pathophysiology of cardiovascular diseases (CVDs). SCs accumulate in the cardiovascular system, leading to typical age-related cardiovascular conditions. Such conditions advance in cardiovascular pathologies, including heart failure, coronary artery disease, cardiac fibrosis, etc., by evocating the production of proinflammatory mediators and profibrotic senescence-associated secretory phenotype (SASP). SCs release different factors depending on the cell type that became senescent. Many factors are responsible for CS with the aging process. The primary senescence causes are oxidative stress, metabolic dysfunction, telomere shortening, and epigenetic deregulation. However, it isn't easy to understand the molecular mechanisms that lead to CS and the consequences of CS in developing new strategies and therapeutic approaches to treat CVDs. Among all, senotherapies are an emerging approach for intervening against CS mechanisms in CVDs to potentially prevent and treat CVDS. Senotherapies allow targeting the underlying causes of aging rather than treating disorders and could reduce polypharmacy. Essentially, senotherapeutics represent an emerging anti-SC treatment and comprise three therapeutic approaches such as molecules to selectively kill SCs that are defined senolytics, compounds able to reduce evocated SC SASP, acting hence as SASP suppressors, called senomorphics, and inhibition of increase of the number of SCs in the cardiovascular tissues. Senotherapies might delay or prevent the CVDs in the elderly. Therefore, senotherapeutics represent the potential clinical application in CVDs, stressing benefits and signifying potential solutions for applying them as soon as effective anti-CVD treatments.</p>\",\"PeriodicalId\":7366,\"journal\":{\"name\":\"Advances in pharmacology\",\"volume\":\"104 \",\"pages\":\"313-349\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Advances in pharmacology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/bs.apha.2025.01.019\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/2/24 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"Pharmacology, Toxicology and Pharmaceutics\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in pharmacology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/bs.apha.2025.01.019","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/24 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0

摘要

细胞衰老(CS)的特征是稳定的细胞周期停滞,并且抵抗与衰老相关的促进生长的刺激。心脏衰老细胞(SCs)是一种高度异质性的细胞,可以调节心血管疾病(cvd)的病理生理。SCs在心血管系统中积累,导致典型的与年龄相关的心血管疾病。这些疾病通过诱导促炎介质和促纤维化衰老相关分泌表型(SASP)的产生,在心血管疾病中发展,包括心力衰竭、冠状动脉疾病、心脏纤维化等。SCs根据衰老的细胞类型释放不同的因子。许多因素导致CS与老化过程。衰老的主要原因是氧化应激、代谢功能障碍、端粒缩短和表观遗传失调。然而,人们并不容易理解导致CS的分子机制以及CS在开发治疗心血管疾病的新策略和治疗方法中的作用。其中,老年治疗是一种干预心血管疾病CS机制以预防和治疗心血管疾病的新兴方法。老年疗法可以针对衰老的根本原因,而不是治疗疾病,并可以减少多种药物。从本质上讲,衰老疗法代表了一种新兴的抗SC治疗方法,包括三种治疗方法,如选择性杀死被定义为衰老剂的SC的分子,能够减少SC SASP的化合物,因此作为SASP抑制剂,称为senomorphics,以及抑制心血管组织中SC数量的增加。老年治疗可以延缓或预防老年人心血管疾病的发生。因此,老年治疗药物代表了cvd的潜在临床应用,强调了其益处,并指出了将其应用于有效的抗cvd治疗的潜在解决方案。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Cellular senescence and senotherapeutics in cardiovascular diseases.

Cellular senescence (CS) is characterized by stable cell cycle arrest and is resistant to growth-promoting stimuli allied with aging. Cardiac senescent cells (SCs) are highly heterogeneous cells that can regulate the pathophysiology of cardiovascular diseases (CVDs). SCs accumulate in the cardiovascular system, leading to typical age-related cardiovascular conditions. Such conditions advance in cardiovascular pathologies, including heart failure, coronary artery disease, cardiac fibrosis, etc., by evocating the production of proinflammatory mediators and profibrotic senescence-associated secretory phenotype (SASP). SCs release different factors depending on the cell type that became senescent. Many factors are responsible for CS with the aging process. The primary senescence causes are oxidative stress, metabolic dysfunction, telomere shortening, and epigenetic deregulation. However, it isn't easy to understand the molecular mechanisms that lead to CS and the consequences of CS in developing new strategies and therapeutic approaches to treat CVDs. Among all, senotherapies are an emerging approach for intervening against CS mechanisms in CVDs to potentially prevent and treat CVDS. Senotherapies allow targeting the underlying causes of aging rather than treating disorders and could reduce polypharmacy. Essentially, senotherapeutics represent an emerging anti-SC treatment and comprise three therapeutic approaches such as molecules to selectively kill SCs that are defined senolytics, compounds able to reduce evocated SC SASP, acting hence as SASP suppressors, called senomorphics, and inhibition of increase of the number of SCs in the cardiovascular tissues. Senotherapies might delay or prevent the CVDs in the elderly. Therefore, senotherapeutics represent the potential clinical application in CVDs, stressing benefits and signifying potential solutions for applying them as soon as effective anti-CVD treatments.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Advances in pharmacology
Advances in pharmacology Pharmacology, Toxicology and Pharmaceutics-Pharmacology
CiteScore
9.10
自引率
0.00%
发文量
45
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信